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A B S T R A C T   
Background: When a new pathogen, such as severe acute respiratory syndrome coronavirus 2, appears all novel 
information can aid in the process of monitoring and in the diagnosis of the coronavirus disease (COVID-19). The 
aim of the current study is to elucidate the specific miRNA profile which can act as new biomarkers for dis-
tinguishing acute COVID-19 disease from the healthy group and those in the post-acute phase of the COVID-19 
disease. 
Methods: The expression level of selected miRNAs including let-7b-3p, miR-29a-3p, miR-146a-3p and miR-155- 
5p were evaluated in peripheral blood mononuclear cells (PBMCs) of COVID-19 patients, in both the acute and 
post-acute COVID-19 phase of the disease and healthy groups, by real-time PCR assays. Specificity and sensitivity 
of miRNAs was tested by receiver operating characteristic (ROC) analysis in COVID-19 patients. 
Results: The expression level of all miRNAs in COVID-19 patients was significantly higher than in the healthy 
group. Therefore, the expression pattern of miR-29a-3p, miR-146a-3p and let-7b-3p in the post-acute COVID-19 
phase was significantly different from the acute COVID-19 phase. ROC analyses demonstrated that miR-29a-3p, 
-155-5p and -146a-3p may serve as the novel biomarker for COVID-19 diagnosis with high specificity and 
sensitivity. In addition, miR-29a-3p, and -146a-3p can maybe act as novel biomarkers for distinguishing acute 
from post-acute phase of COVID-19 disease. 
Discussion: The difference in miRNA expression pattern between COVID-19 patients and those in the healthy 
group, and between acute COVID-19 with post-acute COVID-19, suggested that cellular miRNAs could be used as 
promising biomarkers for diagnosis and monitoring of COVID-19.   
1. Introduction 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
which belongs to the family Coronaviridae, subfamily Coronavirinae, 
genus Betacoronavirus is the causative agent of COVID-19 disease. This 
virus was known as the cause of pneumonia cases in late 2019 in Wuhan, 
China [1–3]. The pandemic of SARS-CoV-2 is spread to more than 200 
countries in the world and has been the causative agent for the death of 
over 2 million people. An additional over 95 million coronavirus cases 
have been detected since composing this article [4]. Novel theories, in- 
depth, and extensive studies are needed to promote novel strategies for 
the management of this viral infection and pandemic outbreaks. 
Based on clinical data, symptomatic cases of COVID-19 are classified 
into three categories: severe, moderate, and mild, however, scientists 
believe that the interpretation of COVID-19 disease conditions and 
progression based on blood biomarkers will be more accurate [5–8]. Due 
* Corresponding author at: Department of Virology, Iran University of Medical Sciences, Tehran, Iran. 
E-mail addresses: bokharaei.f@iums.ac.ir, bokharaeifarah@gmail.com (F. Bokharaei-Salim).  
Contents lists available at ScienceDirect 
International Immunopharmacology 
journal homepage: www.elsevier.com/locate/intimp 
https://doi.org/10.1016/j.intimp.2021.107641 
Received 6 February 2021; Received in revised form 18 March 2021; Accepted 1 April 2021   
International Immunopharmacology 97 (2021) 107641
2
to the limited information available, it is necessary to identify new non- 
invasive biomarkers to differentiate and prognosticate the COVID-19 
disease which is strictly linked to understanding the interaction be-
tween virus and host cell, viral pathogenesis mechanism, and cellular/ 
organ damage [9,10]. The ideal biomarker needs to be easily accessible 
and easily extractable through liquid biopsies from urine, saliva, blood 
and other bodily fluids. Moreover, biomarkers should have good speci-
ficity, high sensitivity, and must also be closely related to the disease 
progression [11–13]. In the last decade, more and more evidence has 
suggested that microRNAs (miRNAs) are promising biomarkers due to 
their high sensitivity and specificity for the diagnosis of various diseases 
such as viral infections and cancers [14–16]. In addition, the expression 
pattern of cellular miRNAs, during the acute phase of the disease, is 
different from the post-acute phase of the disease [17,18]. So, it has the 
ability to be considered as a prognosis biomarker. 
microRNAs are a type of non-coding RNAs with the length 17–25 
nucleotides which play a key role in regulating various biological pro-
cesses such as inflammation, apoptosis, cell proliferation through post- 
transcriptional gene regulation [19,20]. Moreover, cellular miRNAs 
can influence the activity and proliferation of immune system cells in 
response to pathogens [21]. Accumulating evidence has suggested that 
various viral proteins can potentially, directly or indirectly, deregulate 
the expression of cellular miRNAs and by doing so escape the host’s 
immune system by affecting cellular pathways [19,22–25]. Viral acute 
respiratory infections are the most common leading cause of acute res-
piratory tract illness in humans that are in turn responsible for a sig-
nificant proportion of morbidity and mortality. Reportedly, the host 
immune system response against respiratory viruses is associated with 
altered expression levels of cellular miRNAs which, as a result, can lead 
to activate antiviral and inflammatory pathways. On the other hand, as 
mentioned above, viral proteins also escape host antiviral responses 
through the dysregulation of cellular miRNAs [22,26–28]. For viral 
acute respiratory infections (e.g., Rhinovirus, human metapneumovirus, 
Influenza virus, respiratory syncytial virus) miRNAs are involved in both 
the up and down regulations of the innate immune response [27]. It has 
been recently suggested that identification of the miRNA(s) expression 
pattern and their role in viral diseases could lead to the detection of 
novel diagnostic tools and therapeutic targets for viral acute respiratory 
diseases [26]. 
With regard to the interaction between viruses and cellular factors, it 
is possible that the expression pattern of miRNAs during the acute phase 
of disease may be different from the post-acute phase of the disease. 
Since inflammation increases in COVID-19 patients [29–31], it is hy-
pothesized that the expression pattern of miRNA, related to inflamma-
tion (including miR-29, miR-146a, miR-155 and Let-7) [32–38], would 
be different during the acute and post-acute phases of the disease. This in 
turn may be useful for the identification of novel biomarkers for diag-
nosis and prognostic monitoring of COVID-19. Therefore, the aim of this 
study is to investigate the expression pattern of miR-29a-5p, 146a-3p, 
155-5p, and Let-7b-3p in PBMC of Covid-19 virus-infected individuals 
in both the acute and post-acute phases of the disease. 
2. Materials and methods 
2.1. Subjects 
From April 2020 to July 2020, 18 consecutive treatment-naïve 
Covid-19-infected patients were admitted in Valfajr clinic in Tehran, 
Iran (related to Iran University of Medical Sciences), were recruited in 
the current cross-sectional survey. Blood samples were taken from these 
patients twice (once after diagnosis of Covid-19 virus infection by the 
molecular method in the acute period of the disease and the next time in 
the recovery period) and from 15 healthy individuals. 
2.2. Ethical issues 
This study was conducted with the ethical principles and the stan-
dards as well as national norms for performing medical studies in Iran. 
Survey ethical approval was received from Iran University of Medical 
Sciences (IUMS), Tehran, Iran ethics’ committee (ethical code: IR.IUMS. 
REC.1399.223). All individuals provided informed consent to partici-
pate in the study and this survey was performed according to the Second 
Declaration of Helsinki. 
2.3. SARS-CoV-2 real-time RT-PCR 
Total RNA extraction from the nasal, nasopharyngeal, and oropha-
ryngeal swab specimens of all individuals was carried out by using the 
QIAamp Viral RNA Mini Kit (Qiagen, Germany) in accordance with the 
manufacturer’s directions. As well, the real-time RT-PCR assay for the 
qualitative detection of nucleic acid from SARS-CoV-2 (N, and RdRP 
gene detection) was performed according to the Manufacturer’s In-
structions of Sansure COVID-19 Nucleic Acid Test Kit (Sansure Biotech 
Inc.). In addition, to examine the expression levels of selected miRNAs 
after the negative nasopharyngeal RT-PCR test, the RT-PCR test was 
repeated every 15 days for 45 days. 
2.4. Collection of specimens and isolation of peripheral blood 
mononuclear cells (PBMCs) 
Five mL of peripheral blood was taken from each participant into a 
sterile EDTA-containing vacutainer tube and PBMCs were isolated by 
the Ficoll Hypaque density gradient centrifugation (Lympholyte-H, 
Cedarlane, Hornby, Canada) technique. Next, Separated PBMCs were 
washed three times with phosphate-buffered saline (PBS) solution (pH 
= 7.3 ± 0.1) and pleat of PBMCs re-suspended in 250 µL of RNA pre-
servative solution (RNALater, Ambion, Inc., Austin, TX). 
2.5. Total RNA isolation and miRNA expression analysis 
Total cellular RNA was isolated from PBMC specimens using the 
miRNeasy Mini (reference 217004, Qiagen, CA) Kit in accordance with 
the manufacturer’s guidelines. The quantity and quality of the isolated 
RNA were determined on a NanoDrop (Thermo Scientific, Wilmington, 
MA) spectrophotometer and were kept at − 20 ◦C until use. Synthesis of 
cDNA was carried out on 5 μg of total RNA by the miScript® II RT Kit 
(Qiagen, Germany). It is noteworthy that miR-29a-3p, 146a, 155-5p, 
and Let-7b-3p were selected to determine their expression in the two 
stages of acute phase and recovery in PBMC samples of patients with 
SARA-CoV-2 infection as well as healthy individuals based on available 
information. 
The real time PCR assay was performed using the miScript SYBR 
Green PCR Kit (Qiagen, Valencia, CA; #218073), in accordance with the 
manufacturer’s protocols. This assay was carried out at 95 ◦C for 3 min, 
followed by 40 cycles of 95 ◦C for 20 sec, 60 ◦C for 25 sec, and 70 ◦C for 
30 sec, using the Rotor-Gene® real time PCR instrument Q (Qiagen, 
Hilden, Germany). The expression levels of let-7b-3p, miR-29a-3p, miR- 
146a-3p, and miR-155-5p were normalized to SNORD47 RNA as refer-
ence RNA and the fold change was calculated using the Livak [39] 
method. All the reactions were performed in triplicate. 
2.6. Statistical analysis 
All data were analyzed with SPSS version 16.0 and GraphPad Prism 
version 6.0 software. After pre-processing the qPCR data, expression 
level differences of miRNA between the acute COVID-19 group with the 
healthy control group and between the post-acute COVID-19 group with 
the healthy control group were analyzed using the independent-samples 
t-test or the Mann-Whitney U test. In addition, paired sample T-test was 
carried out to examine the statistical difference of the expression level of 
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each miRNA between acute COVID-19 and post-acute phase of COVID- 
19 disease. Receiver-operator characteristic (ROC) curve analysis was 
performed for each miRNA to identify the sensitivity and specificity of 
miRNAs as biomarkers of COVID-19 disease. Also, the Spearman’s cor-
relation coefficient was applied to analysis the association among 
expression level of miRNAs, viral load, N and RdRp genes. In addition, 
the false discovery rate was controlled according to the Benjamini and 
Hochberg procedure, and adjusted P-values were calculated. 
3. Results 
3.1. Characteristics of participants 
Eighteen consecutive COVID-19 infected individuals (in both acute 
and post-acute phases of the disease) and 15 healthy people (as control) 
were enrolled in this cross-sectional survey. Our results show that both 
the study group and the healthy group were matched well for age and 
gender. The mean age of the SARS CoV-2 infected patients was 38.2 ±
11.8 (ranging between 22 and 65 years) and for healthy people was 36.6 
± 12.2 (ranging between 23 and 65 years). Among patients and controls, 
9/18 (50%) and 8/15 (53.3%) were male, respectively (Table 1). The 
clinical and epidemiological characteristics of 18 patients with 
confirmed COVID-19 are described in Table 2. As well, according to the 
result of real-time PCR, mean (±SD) duration of SARS-CoV-2 was 24.17 
± 13.75 days. 
It should be noted that none of the studied COVID-19 virus infected 
patients and healthy people were infected with human immunodefi-
ciency virus-1 (HIV-1 Ag/Ab and HIV-RNA negative), hepatitis C virus 
(HCV Ab and HCV-RNA negative), and hepatitis B virus (HBsAg and 
HBV-DNA negative). 
3.2. Differential miRNA expression in COVID-19 patients and healthy 
subjects 
As shown in Fig. 1, the expression level of miR-29a-3p, 146a-3p, 155- 
5p, and let-7b-3p in acute and post-acute samples was significantly 
higher than in healthy samples (P-value < 0.001). The largest expression 
difference between acute COVID-19 with control groups and between 
post-acute COVID-19 with control groups were observed for miR-155-5p 
(3.75-fold change, P-value < 0.0001) and miR-29a-3p (5.3-fold change, 
P-value < 0.0001), respectively. The expression of miR-29a-3p, miR- 
146a-3p, and let-7b-3p were 3.5, 2.8, and 1.7-fold higher in acute 
COVID-19 patients than in the control group. The comparison of 
expression level of cellular miRNAs between acute and post-acute 
COVID-19 groups with healthy control group was shown in Table 3. 
The results of the Spearman Correlation coefficient analysis between 
miRNAs with SARS-CoV-2 (RdRP and N) genes and demographic and 
clinical characteristics are given in Table 4. According to the result of the 
spearman correlation analysis, a significant negative correlation was 
found between the delta Ct of miR-155-5p and both delta Ct of N (r =
− 0.63, P-value < 0.01) and RdRP (r = − 0.71, P-value < 0.001) genes. 
While, there were no significant correlation between expression level of 
miR-29a-3p, -146a-3p and let-7b-3p with viral factors. 
Also, fold change of miR-29a-3p, -146a-3p, -155-5p were positively 
correlated with Fever (r = 0.51, r = 0.46, and r = 0.56, respectively, 
with all P-value < 0.05). Similarly, a remarkable positive correlation 
was also seen between fold change of miR-29a-3p (r = 0.47, p-value <
0.05), miR-146a-3p (r = 0.49, p-value < 0.05), miR-155-5p (r = 0.49, p- 
value < 0.05) and let-7b-3p (r = 0.73, p-value < 0.0001) with dry cough. 
In addition, there was a positive correlation between miR-146a-3p and 
deceased smell (r = 0.53, P-value < 0.05). More details are presented in 
Table 4. 
3.3. Differential miRNA expression between the acute and post-acute 
phase of COVID-19 disease 
In order to understand whether the expression pattern of selected 
miRNAs after the acute COVID-19 phase will be similar to control levels 
or not, the expression level of miRNAs in confirmed COVID-19 patients 
was re-measured 4–5 weeks after the acute phase. While no significant 
difference in the level of miR-155-5p expression between the acute and 
post-acute groups (P-value = 0.26) were found, the expression profile of 
miR-29a-3p, miR-146 and let-7b-3p were significantly up-regulated in 
acute and post-acute groups (Fig. 2). The results of the study showed 
that expression profile of miR-29a-3p, miR-146 and let-7b-3p were 
different between acute and post-acute groups. Furthermore, mean fold 
change of miR-146 and let-7b-3p were respectively 2.96 and 2.72-fold 
higher in the post-acute group than in the acute group. Furthermore, 
miR-29a-3p was the most upregulated miRNA, with a 3.7-fold change 
compared to that of the acute group (P-value = 0.001). 
3.4. Circulating miRNAs as potential biomarkers for COVID-19 disease 
ROC curve analysis revealed that miR-29a-3p (AUC = 0.91; 95% CI: 
0.82 to 1.0; P < 0.0001), miR-146a-3p (AUC = 0.87; 95% CI: 0.75 to 
0.98; P = 0.0003) and miR-155-5p (AUC = 0.9; 95% CI: 0.78 to 1.0; P <
0.0001) were the useful marker for discriminating between control and 
acute COVID-19 patients (Fig. 3A). Besides, the average fold change of 
miR-146a-3p, miR-155-5p, and let-7b-3p in PBMC of the post-acute 
COVID-19 group compared with the healthy group were 4.45, 4.4, and 
3.1-fold. According to ROC curve analyses, miR-29a-3p, miR-146a-3p, 
and let-7b-3p can differentiate post-acute COVID-19 patients from 
healthy controls, the AUC were 1 (95% CI: 1 to 1; P < 0.0001), 0.98 
(95% CI: 0.96 to 1.0; P < 0.0001) and 0.93 (95% CI: 0.86 to 1.0; P <
0.0001), respectively (Fig. 3B). In addition, miR-29a-3p and miR-146a- 
3p presented good value in distinguishing acute COVID-19 patients from 
post-acute COVID-9 patients with AUC of 0.82 (95% CI: 0.68 to 0.95; p 
= 0.001) and 0.801 (95% CI: 0.65 to 0.95; p = 0.001), respectively, 
(Fig. 3C). 
Table 1 
The demographic features of the studied participants.  
Parameters Male Female Total 
Patients    
Age /Year ± 
SD 
40.8 ± 9.7 
(29–55) 
35.6 ± 13.7 
(22–65) 
38.2 ± 11.8 
(22–65) 
No. of patients 9 (50.0%) 9 (50.0%) 18 (100%) 
Healthy 
people    
Age /Year ± 
SD 
37.9 ± 13.4 
(23–65) 
35.1 ± 11.5 
(22–58) 
36.6 ± 12.2 
(23–65) 
No. of patients 8 (53.3%) 7 (46.7%) 15 (100%)  
Table 2 
The epidemiological characteristics of the studied participants.  
Parameters  Positive Negative 
Epidemiological Characteristics    
Fever  9 (50.0%) 9 (50.0%) 
Confusion  4 (22.2%) 14 (77.8%) 
Headache  10 (55.6%) 8 (44.4%) 
Chills  9 (50.0%) 9 (50.0%) 
Skeletal pain  10 (55.6%) 8 (44.4%) 
Dry cough  7 (38.9%) 11 (61.1%) 
Sputum cough  0 (00.0%) 18 (100.0%) 
Chest pain  3 (16.7%) 15 (83.3%) 
Shortness of breath  5 (27.8%) 13 (72.2%) 
Runny nose  4 (22.2%) 14 (77.8%) 
Cape of nose  5 (27.8%) 13 (72.2%) 
Deceased smell  15 (83.3%) 3 (16.7%) 
Deceased taste  10 (55.6%) 8 (44.4%) 
Gastrointestinal symptom  8 (44.4%) 10 (55.6%) 
Bleeding stomach  1 (55.6%) 17 (94.4%) 
Menstrual disorder Male/9 – –  
Female/9 3 (33.3%) 6 (67.733.3)  
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4. Discussion 
The purpose of our study was to investigate expression pattern of 
cellular miRNAs including Let-7b-3p, miR-29a-3p, miR-146-3p, and 
miR-155-5p between COVID-19 patients with healthy samples and 
during acute and post-acute phase of COVID-19 disease, as well as, 
diagnostic potential of these miRNAs as biomarker. 
Immune system cells respond to the SARS-CoV-2 infection-induced 
damage lung cells through inducing the release of pro-inflammatory 
cytokines (e.g., TNF, IL-6, and IL-1β) which lead to systemic inflam-
mation [40,41]. However, the exact mechanism of the SARS-CoV-2 in-
vasion and the immune system’s aberrant response is not yet well 
understood. In addition to the cellular proteins involved in regulating 
inflammation, it has now been shown which miRNAs also play a critical 
role in regulating the inflammatory process [42]. miR-155 and miR-146 
are among the first miRNAs to be stimulated during immune activation, 
and these miRNAs trigger the production of IFNs and inflammatory 
cytokines through modulating the TLR-signaling pathways [43]. 
Fig. 1. Comparison of miRNAs expression level between COVID-19 patients with healthy controls.  
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Reportedly, the expression level of miR-146a was significantly upregu-
lated in A549 cells infected with the influenza virus and contributes to 
the replication of influenza virus by inhibiting the production of inter-
feron type I [44]. Similarly, the inhibition of miR-146a expressions led 
to a decrease in the expression of matrix and nucleoprotein proteins of 
the influenza virus [45]. Additionally, it has been observed that 
increasing the expression level of miR-146a reduces lung cell damage by 
suppressing inflammatory responses [46]. However, the role of this 
miRNA in the COVID-19 disease has not been investigated. In the cur-
rent study, we found that the expression level of miR-146a-5p was sta-
tistically significantly higher in the COVID-19 patient group than in the 
healthy group (2.8-fold change, P-value < 0.0001, Fig. 1, Table 3). 
Soni et al. [47] investigated the role of miR-155 in SARS-CoV-2- 
mediated pathogenesis. According to the result of this research, miR- 
155-5p level PBMC in COVID-19 patients was higher than in 
individuals from healthy individuals. This study also examined the effect 
of anti-miR-155 on the lungs of SARS-CoV-2- infected hACE2-transgenic 
mice and reported that the inhibition of miR-155 cause promotes sur-
vival and attenuates inflammation and lung cytokine storm induced by 
the virus. The overall results of this study suggested that suppression of 
miR-155 a new therapeutic strategy against decreasing COVID-19- 
induced lung cytokine storm [47]. Additionally, Chow et al. predicted 
that upon infected lung epithelial cells with SARS-CoV-2, the miR-155 
expression level is significantly increased [48]. In another study, Ema-
nuel and colleagues [48] found that the mean expression level of miR- 
155 in Calu-3 cell line infected with SARS-CoV-2 significantly higher 
than the control cell line. Reportedly, miR-155 plays a critical role in 
respiratory viral diseases by the modulation of anti-viral responses, 
including inflammatory and immune responses. For example, in vivo 
inhibition of miR-155 lead to a rapid recovery in influenza virus-infected 
mice [49,50]. In the current study, in line with these studies, the 
expression level of miR-155-5p was significantly upregulated in the 
COVID-19 group compared to the control group (3.75-fold change, P- 
value < 0.0001, Fig. 1). Also, the results of spearman correlation anal-
ysis revealed that a significant inverse correlation was found between 
miR-155-5p with the SARS-CoV-2 N-gene (r = − 0.63, p-value < 0.001), 
and the SARS-CoV-2 RdRp-gene (r = − 0.71, p < 0.0001) (Table 4). 
According to the results, it is possible that the expression of miR-155 is 
increased due to an immune response to fight with SARS-COV-2. 
Recently, Li et al. [51] suggested that cellular miRNAs maybe can 
regulates host immune response and replication of SARS-CoV-2 during 
viral infection. For this purpose, they investigated the profiling of 
cellular miRNAs in PBMC of COVID-19 patients by high-throughput 
sequencing assay, and correlation of miRNAs and their target genes. The 
results of this study showed that expression level of 35 miRNAs (e.g., 
miR-16-2-3p, -6501-5p and -618) were upregulated and 38 miRNAs (e. 
g., miR-183-5p, -627-5p and -144-3p) were downregulated in COVID-19 
patients compared to healthy control. In addition, cluster analysis of this 
study revealed that miR-618 may act as a promising novel target to 
treatment and diagnosis of COVID-19 disease [51]. 
MiRNA target-prediction software is a useful tool for predicting 
targets of miRNAs and identifying cellular miRNAs, due to its ability to 
bind to the virus genome and its ability to act as anti-viral miRNAs [48]. 
Recently, in silico analyses of the interaction between cellular miRNAs 
and the SARS-CoV-2 genome were performed by Jafarinejad-Farsang 
et al. [52]. In this study it was predicted that the sequences of miR-29 
family members have the ability to bind to the SARS-COV-2 genome 
and are bound to the coding sequence for SARS-CoV-2 spike. Further-
more, miR-146a, let-7b, let-7e, miR-21 and miR-16 were identified as 
miRNAs targeting differentially expressed genes (DEGs) in SARS-CoV-2 
infected lung cells [52]. Ma and colleagues [53] found that let-7c was 
significantly overexpressed in influenza-infected A549 cells and that it 
can act as an anti-influenza miRNA through reduction of M1 protein of 
HINI influenza A in A549 cells [53]. Moreover, Inchley et al. [54] 
investigated the expression pattern of cellular miRNAs in the nasal 
mucosa of respiratory syncytial virus (RSV)-infected infants. They 
observed that expression levels of let-7d, miR-155, -203a, -31 and -16 in 
the RSV-infected infants’ group were higher than in the control group. 
However, the expression level of miR-29c, -27b, -34b, -34c, -125b, 125a 
and -429 were found to be significantly downregulated in the RSV- 
infected infant group compared to the control group [54]. However, 
changes in the expression of miR-29a-3p and let-7 during the COVID-19 
disease and its role in SARS-CoV-2 viral infection have not yet been 
reported. In the present study, for the first time, it was observed which 
the expression patterns of these miRNAs in the COVID-19 group (3.5- 
fold for miR-29a-3p) were significantly higher than in the control group 
(1.7-fold for let-7b-3p) (Fig. 1 and Table 3). 
When a new pathogen or new strains of a pathogen appear, all novel 
information can help the process of monitoring, treatment, and diag-
nosis of the disease. One of the new candidates for diagnosis and therapy 
is miRNAs, which may serve as a useful tool in laboratory medicine [55]. 
Table 3 
Comparison of miRNAs expression level between acute and post-acute COVID- 




vs Control group 
Post-Acute COVID- 
19 vs Control 
group 





F: 3.5 F: 5.3 F: 3.4  
T: 6.3 T: 12.8 T: 3.7  
P: <0.0001 P: <0.0001 P: 0.001 
miR-155- 
5p 
F: 3.7 F: 4.4 F: 1.3  
T: 5.06 T: 10 T: 1.14  
P: <0.0001 P: <0.0001 P: ns 
miR-146a- 
3p 
F: 2.8 F: 4.4 F: 2.9  
T: 4.38 T: 8.9 T: 3.5  
P: 0.0001 P: <0.0001 P: 0.002 
Let-7b-3p F: 1.7 F: 3.1 F:2.7  
T: 3.2 T: 6.3 T: 3.1  
P: 0.002 P: <0.0001 P: 0.006 
F: Fold change (log2), T: t-value, P is adjusted P-value based on the marginally 
adjusted p values by the Benjamini-Hochberg-FDR correction at α = 0.05. 
Table 4 
Spearman’s correlation coefficient between the miRNA’s expression level with 
expression level of viral genes (N and RdRp genes), demographic and clinical 









N gene 0.27 ns − 0.28 ns − 0.63** − 0.12 ns 
RdRp − 0.3 ns − 0.32 ns − 0.71*** − 0.13 ns 
Sex 0.18 ns 0.21 ns 0.29ns 0.07 ns 
Age 0.18 0.04 − 0.108 0.07 ns 
Fever 0.51* 0.46* 0.56* 0.36 ns 
Confusion 0.05 ns 0.07 ns − 0.04 ns 0.07 ns 
Headache − 0.1 ns − 0.17 ns − 0.08 ns − 0.25 ns 
Chills 0.04 ns − 0.16 ns 0.04 ns − 0.01 ns 
Skeletal pain − 0.05 ns − 0.19 ns − 0.03 ns − 0.19 ns 
Dry cough 0.47* 0.49* 0.49* 0.73*** 
Sputum cough − 0.01 ns 0.05 ns 0.004 ns 0.071 ns 
Chest pain − 0.09 ns − 0.13 ns 0.07 ns 0.11 ns 
Shortness of breath − 0.27 ns − 0.28 ns − 0.15 ns 0.01 ns 
Runny nose − 0.02 ns − 0.13 ns − 0.05 ns 0.17 ns 
Cape of nose − 0.17 ns − 0.206 ns − 0.06 ns − 0.16 ns 
Deceased smell 0.39 ns 0.53* 0.44 ns 0.42 ns 
Deceased taste 0.09 ns 0.15 ns 0.3 ns 0.35 ns 
Gastrointestinal 
symptom 
0.15 ns 0.19 ns 0.17 ns − 0.35 ns 
Bleeding stomach 0.01 ns − 0.21 ns − 0.005 ns − 0.35 ns 
ns: not significant. 
* P < 0.05. 
** P < 0.01. 
*** P < 0.001. 
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Conceptually, to identify candidate miRNAs there are two main ways: 1) 
evaluation of the pathogenic agent effect on the expression level of 
cellular miRNAs, 2) checking the role of miRNA on the pathogen life 
cycle by the knock-outing or enforcing the expression of miRNA [56]. In 
the current study, the expression level of selected miRNAs is signifi-
cantly different between the COVID-19 group and the healthy group 
(Fig. 1). It is also found to be different between acute and post-acute 
COVID-19 (Fig. 2). Additionally, the result of ROC analysis shows that 
miR-29a-3p (AUC: 0.91, P-value < 0.0001), miR-155-5p (AUC: 0.9, P- 
value < 0.0001), and miR-146a-5p (AUC: 0.87, P-value: 0.0003) may be 
used as a potential diagnostic marker for COVID-19 vs healthy subjects 
(Fig. 3). 
More recently, some studies have reported that after the acute phase 
of the COVID-19, patients still experience some clinical symptoms of 
disease such as fatigue, weakness, and headache, low grade fever, and 
cough [57,58]. These symptoms are believed to be prevalent during 
post-acute COVID-19 phase and do not depend on prior health status, or 
the severity of acute COVID-19 illness [58]. 
Recently, Zheng and colleagues [59] analyzed the transcriptome 
profiles including mRNA, miRNAs, and long noncoding RNAs (lncRNAs) 
in PBMC of COVID-19 patients with mild, moderate, and severe symp-
toms during their treatment, convalescence, and rehabilitation. The 
result of their study showed that downregulation of humoral immunity 
and IFN-I response, as well as T cell activation and differentiation, were 
the main events that occurred during the recovery phase of COVID-19 
disease. Also, they reported that expression level of let-7b-5p, miR- 
103a-2-5p, -200c-3p and -2115-3p was decreased during recovery from 
COVID-19 disease and these miRNAs are involved in the regulation of T 
cell differentiation [59]. Further, in the present research, the level of 
selected miRNAs, after about 4–5 weeks of the acute COVID-19 phase 
(Post-acute COVID-19), was examined and the expression level of miR- 
29a-3p, -146a-3p and let7b-3p in the post-acute COVID-19 group were 
3.7, 2.9 and 2.7-fold higher respectively than in the acute COVID-19 
group (Fig. 2). However, there was no significant difference in the 
mean expression level of miR-155-5p between the two groups (Fig. 2). 
By contrast to Zheng and colleagues [59] reports, in our study observed 
that expression level of let-7b-5p in acute phase of COVID-19 disease 
significantly higher than that post-acute COVID-19. 
Moreover, ROC curve analysis demonstrated that the high sensitivity 
and specificity for miR-29a-3p and miR-146 offers potential biomarkers 
for discriminating acute from the post-acute COVID-19 phase (Fig. 3). 
The difference in the miRNA expression pattern during the acute and 
post-acute phase of COVID-19 disease proposed which cellular miRNAs 
can be used as novel biomarkers for monitoring of COVID-19 disease. 
Fig. 2. Comparison of the expression pattern of miRNAs in the COVID-19 patients during Acute and Post-acute COVID-19 disease.  
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In conclusion, this study was the first report of differentially 
expressed miRNA profile including let-7b-3p, miR-29a-3p, miR-146a-3p 
and miR-155-5p in COVID-19 group and healthy group, and also during 
the acute and post-acute phase of the COVID-19 disease. As a result, we 
found that the expression level of miRNAs was upregulated in the PBMC 
specimens of COVID-19 patients and post-acute COVID-19 phase. A 
sequence of transcription factors (TFs) plays critical roles in COVID-19 
pathogenesis. In these regards, performance of construction and anal-
ysis of miRNA-TF regulatory network indicated that the measured 
miRNAs could be associated with some genes (i.e., NF-kB) that are 
involved in COVID-19 progression (Fig. 4). In addition, specificity and 
sensitivity of these miRNAs was tested by ROC analysis in COVID-19 
Fig. 3. ROC curve analysis using PBMC miR-29a-3p, miR-146a-3p, miR-155-5p, and let-7b-3p for discriminating control and COVID-19 patients. miR-29a-3p, -146a- 
3p, and-155-5p were able to diagnose acute COVID-19 disease as compared with healthy controls (A-C). PBMC miR-29a-3p, -146a-3p, and let-7b-3p were useful to 
diagnose acute COVID-19 disease as compared with healthy control (D-F) as well as, miR-29a-3p and -146a-3p were the good marker for discriminating between 
acute and Post-acute COVID-19 diseases (G-H). 
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patients and it was observed that miR-29a-3p, miR-155-5p and miR- 
146a-3p may be used as a potential diagnostic marker for diagnosis of 
acute-COVID-19 disease and also miR-29a-3p, and miR-146a-3p can 
probably act as novel biomarkers for distinguishing post-acute from 
acute phase of COVID-19 disease. The small sample size and the lack of 
other respiratory disease as controls were the limitations of this study, so 
more studies with larger volunteers are needed to show the diagnostic 
value of these miRNAs as diagnostic biomarker for COVID-19. 
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